

June 28-30, 2022 | San Francisco
www.longevity-therapeutics.com

**BOOK BEFORE
JUNE 28 & SAVE
UP TO \$100**



4th Annual **LONGEVITY** therapeutics

**Slow, Freeze & Reverse Aging &
Age-Related Diseases by Targeting
Stem Cell Exhaustion, Epigenetic
Reprogramming, Cellular Senescence,
Cell Signaling & Metabolism**

Expert Speakers Include:



Erin Kimbrel
Vice President, Research
**Astellas Institute for
Regenerative Medicine**



Louis Hawthorne
Chief Executive Officer
NaNotics



Michael Fossel
President
Telocyte



Viktoria Kheifets
Senior Vice President
Alkahest



Kate Batz
Director
Deep Knowledge Investors



Guna Rajagopal
Scientific Vice President
& Fellow
Janssen



Robin Mansukhani
Chief Executive Officer
Deciduous Therapeutics



Nir Barzilai
Director
**Einstein Institute For
Aging Research**

Proud to Partner With:



Welcome to 4th Annual Longevity Therapeutics Summit



June 28-30, 2022
San Francisco

Join Us on the Ambitious Quest to Cure Age-Related Diseases & Aging as a Disease

The **4th Annual Longevity Therapeutics Summit** returns to San Francisco this summer where it remains the **only industry meeting** uniting leading biotech/pharma drug developers, pioneering academics, and prominent investors, striving to develop effective, novel anti-aging drugs and overcome major preclinical, translational, clinical, and regulatory obstacles.

This **in-person meeting** will reveal the field's cutting-edge technology advancements from leading minds in the longevity community. This summit is your **one-stop forum to fast-track the development of anti-aging drugs aiming to enhance healthspan**, whilst uncovering the key R&D challenges limiting the development of these therapies.

With an influx of investments into the anti-aging space, **2022 is set to be a record year for research and funding in the burgeoning longevity field**. Furthermore, with the FDA continuing to deny aging as an indication, a lack of robust surrogate biomarkers for aging and the high cost of running trials that measure the lifespan in humans, now is the time to come together as a community to solve the longevity community's toughest challenges.

Join your peers from **Deep Longevity, Biophytis, Elevian, Rubedo Life Sciences** and many others and delve into exclusive case studies discussing **cellular senescence, telomere attrition, loss of proteostasis, stem cell exhaustion, mitochondria, metabolism and more**.

Leave equipped with novel ideas, actionable insights, and new connections to **accelerate your progression from pipeline to clinic and develop truly curative anti-aging therapeutics**.

Calling All Longevity Enthusiasts!

I am delighted to welcome you to the most hotly anticipated longevity event this year, the **4th Annual Longevity Therapeutics Summit**. Returning for its 4th edition in-person, this is your comprehensive guide to overcome the unique drug development challenges encountered in progressing truly curative anti-aging drugs.

This year's summit will provide in-depth insights from experts with experience-driven clinical progress and methods to overcome preclinical, translational, regulatory, and clinical challenges.

Across three days of carefully curated sessions, we will gather 80+ pioneering minds in longevity therapeutics who will discuss key topics from progressing pipelines through the clinic to utilizing next-generation technologies such as artificial intelligence and machine learning to bring therapies to patients quickly, effectively, and safely.

I am excited to unite as a community in San Francisco this June and hear from key biotech, pharma, academics, investors, and regulators at the forefront of the field, share critical learnings and make valuable connections to drive longevity drug development.

If you are working to develop truly novel anti-aging therapeutics to extend the human healthspan, then I hope you can join your community as we work to overcome debilitating age-related diseases and strive towards curing aging as a disease.



Yours sincerely,

Elisha Malik

Program Director
Hanson Wade

Top 5 Reasons to Attend the 4th Annual Longevity Therapeutics Summit



Discuss methods to accelerate the conversion of biomarkers into registrable endpoints for regulatory development in longevity therapeutics with the **Longevity Biotech Association** and **Alkahest**



Discover the latest cutting-edge technologies being used in longevity therapeutics including artificial intelligence, machine learning, multi-omics, and big data with **Leucadia Therapeutics, Deep Longevity, Fountain Therapeutics** and the **Furman Lab and AI Platform**



Hear from leaders in the field such as **Deciduous Therapeutics, NaNotics** and **Rubedo Life Sciences** as they discuss the potential of senotherapeutics and senolytics in longevity therapeutics



Understand the challenges in progressing towards the clinic and how to fund and conduct long-term clinical trials with Michael Fossel, **Telocyte** and John Cooke, **Houston Methodist Academic Institute**



Join critical conversations: Reunite with leaders in the industry, have your opinions heard, and showcase your work with **over 10 hours of in-person networking** and a **scientific poster session**

Your Expert Speakers



June 28-30, 2022
San Francisco



Anastaysia Giarletta
Principal
R42 Group



Guna Rajagopal
Scientific Vice
President & Fellow
Janssen



Andrei Gudkov
Chief Scientific Officer
Genome Protection



Anurag Singh
Chief Medical
Officer
Amazentis



Benjamin Yaden
Senior Director, Advisor
Eli Lilly



Birgit Schilling
Associate Professor,
Proteomics & Aging
**Buck Institute for
Research on Aging**



David Furman
Associate Professor,
Proteomics & Aging
**Buck Artificial
Intelligence
Platform**



Doug Ethell
Chief Executive Officer
**Leucadia
Therapeutics**



Erin Kimbrel
Vice President,
Research
**Astellas Institute
for Regenerative
Medicine**



John Cooke
Chief Translational
Sciences Officer
**Houston Methodist
Academic Institute**



Karl Pflieger
Founder
AgingBiotech.info



Matt Kaeberlein
Professor
**University of
Washington**



Kate Batz
Director
**Deep Knowledge
Investors**



Keshav K Singh, PhD
Chief Scientific Officer
Yuva Biosciences



Louis Hawthorne
Chief Executive
Officer
NaNotics



Marco Quarta
Co-Founder & Chief
Executive Officer
**Rubedo Life
Sciences**



Mark Allen
Co-Founder & Chief
Executive Officer
Elevian



Michael Fossel
President
Telocyte



Michelle Keller
Senior Manager of
Scientific BD
**Deep Longevity
Limited**



Misha Shchepinov
Chief Scientific
Officer
Retrotope



Nir Barzilai
Director
**Einstein Institute
For Aging
Research**



Pinchas Cohen
Dean
**Leonard Davis
School of
Gerontology**



Robin Mansukhani
Chief Executive
Officer
**Deciduous
Therapeutics**



Stanislas Veillet
Chief Executive
Officer
Biophytis



Viktoria Kheifets
Senior Vice President
Alkahest



Joe Rodgers
Director of Biology,
Co-Founder
**Fountain
Therapeutics**



Erik Stoops
Head of
Development
**ADx
NeuroSciences**



Joe Sarret
Chief Executive
Officer
CohBar



Jim McGuire
Head of Discovery
**Juvena
Therapeutics**

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Pre-Conference Workshop Day

Tuesday June 28, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



9.00 Welcome Coffee & Registration

Workshop A

9.45 Addressing the Key Challenges in Progressing Towards the Clinic in Longevity Therapeutics



Michael Fossel
President
Telocyte



John Cooke
Chief
Translational
Sciences Officer
Houston
Methodist
Academic
Institute

In this dynamic and fast-growing field, many successful preclinical trials are unable to make it to the clinic. This evidence-based workshop will explore the greatest challenges in progressing towards the clinic and explore different methods to overcome these challenges.

Another key challenge facing the longevity field sits with the FDA not recognizing aging as an indication. As such, this interactive workshop will provide a platform to discuss how to advance towards regulatory approval, recognize indications in age-related diseases and develop drugs solely from a longevity perspective.

Join this workshop to be a part of the discussion between leading minds in the longevity field as they:

- Outline the core challenges in moving towards the clinic
- Examine the failures in early-stage trials that are preventing progression towards the clinic
- Work alongside the FDA and large pharma to develop longevity-specific drugs
- Discuss how to select indications specific to aging while also obtaining regulatory approval



12.15 Networking Refreshment Break

Workshop B

1.15 Challenging the Traditional Model for the Hallmarks of Aging



Marco Quarta
Co-Founder &
Chief Executive
Officer
Rubedo Life
Sciences



Jim McGuire
Head of
Discovery
Juvena
Therapeutics

The hallmarks of aging have provided a useful model for aging in the longevity field and have been the inspiration behind many drug development pipelines for age-related diseases. However, as the longevity field progresses, it is crucial to discuss whether the hallmarks of aging are becoming too restrictive and if recent industry developments have allowed us to move past this highly simplified model of aging.

Join this deep-dive workshop to:

- Discuss which hallmarks of aging are the most popular targets for drug development and why
- Evaluate whether targeting individual hallmarks or a cocktail of hallmarks is most effective in longevity therapeutics
- Recognize that the hallmarks of aging were modelled from oncology and discuss the limitations of this
- Assess whether such a simplified model of aging is helpful or harmful in longevity drug development

3.45 Workshop Leaders' Closing Remarks & End of Pre-Conference Workshop Day

Great conference experience!

President, CohBar



Good quality content

Senior Director, Pfizer



Conference Day 1

Wednesday June 29, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.00 Registration & Morning Coffee

Michael Fossel
President
Telocyte

8.50 Chair's Opening Remarks

Accelerating the Conversion of Biomarkers of Aging into Registrable Endpoints

Nir Barzilai
Director
Einstein Institute for
Aging Research

9.00 Can We Save Time in a Bottle?

- Discussing human genetic studies to confirm drug targets
- Exploring biomarkers for longevity therapy
- Considering TAME-paving the road for FDA approval of gerotherapeutics

Erik Stoops
Head of Development
ADx NeuroSciences

9.30 Utilizing Biomarker Assays to Diagnose a Variety of Neurodegenerative Diseases

- Exploring the potential of biomarker assays to revolutionize the diagnostic workup of Alzheimer's disease
- Assessing the future of relevant biomarkers being discovered in Parkinson's, general neurodegeneration, and glial activation
- Considering an overview of the latest advancements in the field of biomarkers for neurodegenerative diseases
- Discussing directions regarding implementation of novel biomarkers in clinical practice and trials

Viktoria Kheifets
Senior Vice President
Alkahest

10.00 Molecularizing the Science of Plasma to Therapeutically Target Diseases of Aging

- Discussing an integrated 'omics' approach to identify protein drivers of health and disease in plasma to therapeutically impact trajectory of aging
- Evaluating the clinical progress in advancing from understanding of the plasma proteome to therapeutics in age-related disorders



10.30 Speed Networking Break

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the longevity field and establish meaningful business relationships to pursue for the rest of the conference.

11.30 Panel Discussion: The Lack of Robust Surrogate Biomarkers for Aging

Join keynote speakers as they discuss the lack of robust biomarkers in the longevity field and methods to overcome this including:

- Evaluating novel biomarkers that may correlate to registrable endpoints in longevity therapeutics
- Assessing how to move novel biomarkers towards regulatory approval
- Discussing the importance of developing defined biomarkers for aging and how we can use robust biomarkers to move the longevity field forward



Nir Barzilai
Director
Einstein Institute for
Aging Research



Erik Stoops
Head of Development
ADx NeuroSciences



Viktoria Kheifets
Senior Vice President
Alkahest

Conference Day 1

Wednesday June 29, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

The Rise of Senolytics: What is the Future of Cell Senescence in Longevity Therapeutics?



Birgit Schilling
Associate Professor,
Proteomics & Aging
**Buck Institute for
Research on Aging**

12.00 Highlighting Senescence-Derived Biomarkers of Aging & Osteoarthritis

- Discussing the development of panels of proteins which serve as markers for aging phenotypes in order to monitor potential therapeutic interventions
- Zooming in on senescence-derived biomarkers of aging
- Assessing senescence markers in cartilage and bone targeting underlying mechanisms and options for intervention for osteoarthritis

Robin Mansukhani
Chief Executive
Officer
**Deciduous
Therapeutics**

12.30 Harnessing Endogenous Immune Biology to Ablate Pathogenic Senescent Cells & Treat Disease

- Discussing therapeutically harnessing the immune system to remove senescent cells in a disease state
- Achieving therapeutically relevant endpoints and durable effects
- Outlining how there has been a paradigm shift for systemically treating age related multi-morbidities



1.00 Lunch & Networking

We are proud to partner with Maxwell Biosciences who will be hosting an exclusive lunch for Longevity Experts in the field.



Keshav K Singh, PhD
Joy and Bill Harbert
Endowed Chair &
Professor
**Heersink School of
Medicine, University
of Alabama at
Birmingham**
Chief Scientific
Officer
Yuva Biosciences

2.00 Mitochondria as Reversible Regulators of Skin Wrinkles & Hair Loss

- Explaining how mitochondrial dysfunction leads to skin aging and loss of hair
- Understanding how restoring mitochondrial function restores hair and mitigates skin wrinkles
- Analyzing why mitochondria-regulated epigenetic changes play a key role in the reversal of skin aging and hair loss

VIRTUAL
TALK

Marco Quarta
Co-Founder & Chief
Executive Officer
**Rubedo Life
Sciences**

2.30 Computational Discovery of Cellular Senescence in Age-Related Diseases to Develop Selective Senolytics

- Discussing the definition of senescent cells as heterogeneous cell populations and considering that not all senescent cells are pathological cells
- Assessing bioinformatic strategies that enable the discovery of senescent cell types to target in specific age-related diseases
- Examining the development of selective novel classes of senolytics for effective pharmacological strategies to treat age-related diseases

3.00 Roundtable Discussion: An Evaluation of the Rise of Senolytics & the Future of Targeting Senolytic Cells

Join your session leaders in this roundtable as they spark conversation on:

- The sudden rise in targeting senescent cells
- Novel clinical and preclinical trials that are progressing in the senescent space
- Discussing whether research should be focus solely on cellular senescence or take a cocktail approach alongside other hallmarks of aging



Birgit Schilling
Associate Professor,
Proteomics & Aging
**Buck Institute for
Research on Aging**



Robin Mansukhani
Chief Executive Officer
**Deciduous
Therapeutics**



Marco Quarta
Co-Founder & Chief
Executive Officer
Rubedo Life Sciences

Conference Day 1

Wednesday June 29, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



3.30 Poster Networking Session

Join your peers to discover the latest developments and breakthroughs, grow your network of meaningful industry connections and showcase your work to colleagues in the longevity field.

Turning Back Time with an Epigenetic Clock & Novel Preclinical & Clinical Trials that are Promoting Regeneration

Matt Kaerberlein
Professor
University of Washington

4.00 Can Rapamycin Safely Delay or Reverse Aging Outside the Lab?

- Discussing how Rapamycin is the most effective and reproducible drug for increasing lifespan and healthspan metrics in laboratory animals
- Analyzing anecdotal data from people taking low dose rapamycin is suggestive of benefits for healthspan
- The effects of rapamycin on age-related indications are beginning to be tested in randomized clinical trials

Erin Kimbrel
Vice President,
Research
Astellas Institute
for Regenerative
Medicine

4.30 Developing Pluripotent Stem Cell-Based Therapies for the Treatment of Age-Related Diseases

- Examining how pluripotent stem cells (PSCs) are a key starting material for the development of off-the-shelf cell-based therapies to help treat patients with high unmet medical needs
- Outlining the key challenges in the value chain of PSC-based therapies and discussing strategies to overcome these challenges
- Analyzing how overcoming immunogenicity will help improve and expand the clinical application of allogeneic PSC-based therapies
- Discussing how the marriage of gene editing technologies with PSC technology is helping to create the next generation of engineered cell therapies that go above and beyond what naturally occurring cells of a patient's body can do

Guna Rajagopal
Scientific Vice
President & Fellow
Janssen

5.00 Exploiting Large Scale Human Genetics Data to Advance Pharmaceutical Research in Aging Related Diseases

- Through a public-private partnership, we have successfully generated whole genome sequence on all 500,000 samples from volunteers in the UK Biobank
- Linked with rich phenotype data collected on these individuals, we have the capability to enable better understanding of the biology of aging related diseases
- We will outline our efforts to develop and deploy computational infrastructure and data science capabilities to translate this massive data set into pharmacological insights
- We encourage engagement with academic and industry partners to facilitate and advance our therapeutic strategy to discover and deliver safe and effective medicines in this space

Mark Allen
Co-Founder & Chief
Executive Officer
Elevian

5.30 Using Recombinant Protein GDF11 to Promote Recovery Post Stroke

- Exploring how GDF11 plays an important role in aging, regeneration and repair
- Analyzing evidence that recombinant GDF11 (rGDF11) promotes recovery post stroke
- Discussing why Elevian is sponsoring rGDF11 clinical trials to promote recovery from stroke and other aging-associated diseases

Andrei Gudkov
Chief Scientific
Officer
Genome Protection

6.00 Examining Anti-Aging Therapies Targeting Endogenous "Retrobiome" & Immunosenescence

- Discussing how aging is associated with genetic and epigenetic modulations of somatic cells accompanied with progressive immunosenescence
- Assessing new insights into the intrinsic mechanisms of DNA damage, age-related inflammation and immunosenescence
- Examining approaches to their therapeutic correction with small molecules targeting LINE-1 retrotransposons and immunomodulators will be presented

6.30 Chair's Closing Remarks & End of Day One

Conference Day 2

Thursday June 30, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



8.50 Chair's Opening Remarks

Smart Investments: How to Invest in Longevity

Karl Pfleger
Founder
[AgingBiotech.info](https://agingbiotech.info)

9.00 A Broad Overview of the Aging/Longevity Investment & Startup Landscape

- Assessing the 100+ companies now working in the longevity field and the success some have had in extending the lifespan in animals and evaluating the potential to progress this into human longevity
- Analyzing breakdowns of the startups in the field
- Considering overall trends in the space as a whole
- What's missing when viewing the whole field as a pipeline?

Kate Batz
Director
[Deep Knowledge Investors](https://deepknowledgeinvestors.com)

9.30 Longevity-Derived Financial Instruments as Practical Implementation of Longevity Biomarkers

- Explaining that biomarkers of human longevity possess valuable and precise information about the life expectancy of a given person or cohort. This implies that biomarkers-based methods have a significant impact on longevity risks mitigation
- Discussing the variety of financial instruments that are highly exposed to longevity risks:
 - Equity reverse mortgage, allowing enhanced longevity risks optimization for both the customer and the provider
 - Loan management for retirees
 - In longevity annuity contracts-providing feasible means for risk hedging
 - Longevity-tied derivatives can benefit from the implementation of the biomarkers-based longevity indices

Anastaysia Giarletta
Principle
[R42 Group](https://r42group.com)

10.00 Focusing on Investments in AI/Deep Tech & Biotech/Longevity

- Navigating the investment landscape in longevity with respect to artificial intelligence, deep tech and machine learning

10.30 Panel Discussion: Investing in Longevity

Join leaders from venture capital, large pharmaceuticals and innovative biotechs as they discuss how to navigate investments and funding in this lucrative field

- Outlining the current longevity/aging investment and startup landscape
- Discussing the investment potential in this lucrative field
- Analyzing areas that could be improved upon in this field



Anastaysia Giarletta
Principle
[R42 Group](https://r42group.com)



Kate Batz
Director
[Deep Knowledge Investors](https://deepknowledgeinvestors.com)



Karl Pfleger
Founder
[AgingBiotech.info](https://agingbiotech.info)



Joe Sarret
Chief Executive Officer
[CohBar](https://cohbar.com)



11.00 Morning Networking Break

Conference Day 2

Thursday June 30, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Evaluating the Progress in Longevity Therapeutics Targeting Mitochondrial Dysfunction & Metabolic Diseases

Louis Hawthorne
Chief Executive
Officer
NaNotics

- 11.30 Get Your Signals Straight: Extending Healthspan with NaNotics Against Pathogenic Signals & Inhibitors**
- The Signalome & role in disease & aging
 - What are NaNotics?
 - Targeting soluble immune inhibitors as senolytics (FDA disease is cancer – targets are the same)
 - Targeting inflammatory cytokines to treat “Inflamm-aging” (FDA disease is sepsis – targets are the same)
 - Ultimate vision of NaNotics as “signal tweakers” for maintaining health

Anurag Singh
Chief Medical Officer
Amazentis

- 12.00 Discussing Mitophagy Activation Via the Natural Postbiotic Urolithin A to Boost Mitochondrial Health During Aging**
- Outlining mitophagy activation as a key anti-aging strategy to boost mitochondrial health
 - Exploring the discovery of the gut microbiome postbiotic Urolithin A to activate mitophagy
 - Analyzing clinical evidence from different RCTs showing the potential of Urolithin A to improve mitochondrial health during aging

Misha Shchepinov
Chief Scientific
Officer
Retrotope

- 12.30 Exploring the Heavy Handling of Age-Related Diseases that Involve Lipid Peroxidation**
- Examining evidence that suggests that lipid peroxidation is an overlooked common denominator of various age-related pathologies
 - Analyzing the reasons why antioxidants are inefficient
 - Understanding the isotope reinforcement of changes essential lipids chemically, without changing them chemically

Pinchas Cohen
Dean
**Leonard Davis
School of
Gerontology**

- 1.00 Highlighting the Mitochondrial Micro-Proteome as a Platform for Healthspan-Related Drug Discovery**
- Discussing how the mtDNA contains hundreds of previously unrecognized small open-reading frames that encode a novel class of mitochondrial-derived peptides (MDPs)
 - Exploring several new and innovative bioinformatic approaches that allow the discovery of disease relevant MDPs that can serve as targets for diseases of aging
 - Evaluating specific MDPs that are mutated in conditions such as diabetes and Alzheimer's disease represent novel precision-aging treatment strategies



- 1.30 Lunch Break**
- Take this opportunity to meet our expert speakers, connect with your peers and explore solutions and products in our exhibition booths

Implementing Artificial Intelligence & Machine Learning in Longevity Therapeutics

Stanislas Veillet
Chief Executive
Officer
Biophytis

- 2.15 Discussing the Use of Sarconeos (BIO101) for the Treatment of an Emerging Age-Related Disease, Covid-19**
- Outlining Covid-19 as an age-related disease
 - SARS-Cov-2, the Renin Angiotensin System and Severe Acute Respiratory Syndrome
 - Sarconeos (BIO101), a MAS activator for the treatment of Covid-19 in elderlies

Conference Day 2

Thursday June 30, 2022



June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE



Doug Ethell
Chief Executive
Officer
**Leucadia
Therapeutics**

2.45 **Treating Alzheimer's Disease by Draining Detritus from the Brain**

- Using artificial intelligence to show that aging reduces the brain's clearance of metabolites
- Explaining the effects of an implantable device which restores the clearance mechanism
- Reviewing preparation for clinical trials of the Arethusta device which begins in 2023

Michelle Keller
Senior Manager of
Scientific BD
**Deep Longevity
Limited**

3.15 **Aging Clocks as the Foundation of the Emerging Longevity Industry**

- Discussing the aging clock which is a technology whose primary purpose is to measure the pace of aging
- Using the aging clock to evaluate the efficacy of a longevity therapy or as a recommendation engine to guide a person towards healthy longevity
- Deliberating how the functions of the aging clock promise to revolutionize the healthcare, insurance, and food industries



3.45 **Afternoon Coffee Break**

David Furman
Associate Professor,
Proteomics &
Aging
**Furman Lab & Buck
AI Platform**

4.00 **Human Aging & Longevity: The Immune System Takes the Lead**

- Examining how over the past decade it has become apparent that the immune system determines, at large, the rate of aging
- Discussing how using multi-omic approaches, AI/ML, and systems biology methods in large cohorts, it is now possible to derive biomarkers and mechanisms of immune-mediated aging rates
- Integrative analysis of these multiple layers of biological information can yield efficacious and safe longevity interventions

Joe Rodgers
Director of Biology,
Co-Founder
**Fountain
Therapeutics**

4.30 **Using Artificial Intelligence in Drug Discovery & Development for Diseases of Aging: Opportunities & Considerations**

- Building classification models for diseases of aging
- Evaluating the use of AI for unbiased drug screening
- Discussing the potential of AI in drug development for aging diseases beyond discovery

Progressing Towards the Clinic

Michael Fossel
President
Telocyte

5.00 **Reversing Cell Aging in Human Trials: The CNS, Cardiovascular System, & Other Tissues**

- Aging: What it is and what are we missing?
- Exploring cell aging in molecular detail and its clinical implications
- Discussing the optimal point of intervention clinically and financially

John Cooke
Chief Translational
Sciences Officer
Houston Methodist

5.30 **Discussing the Emerging Field of Using an RNA Therapeutic for Age-Related Disorders**

- Highlighting the rapidly emerging field of mRNA therapeutics and exploring why it will have a transformative effect on clinical care, including age-related diseases
- Analyzing why vascular aging is the underlying cause of most morbidity and mortality, including heart attack and stroke, as well as dementia and other age-related disease
- Examining proof-of-concept studies in iPSC-derived vascular cells and murine models of aging, using a novel mRNA therapeutic

6.00 **Chair's Closing Remarks**

Proud to Partner With

Event Hosting Partner



Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented small molecule drugs that destroy SARS-CoV-2, the COVID virus, and other viruses. This first-in-class CLAROMER Brand drug platform mimics natural human immune system antimicrobial and antiviral peptides.

www.maxwellbiosciences.com

Great conference experience!

President, **CohBar**



Good quality content

Senior Director, **Pfizer**



Very professional event. Great timing

Co-Founder and CEO, **Elevian**



GET INVOLVED



Kieran Crewe
Partnerships Director
Tel: (+1) 6174554188
Email: sponsor@hansonwade.com

Why Partner with the Longevity Therapeutics Summit?



4th Annual
June 28-30, 2022
San Francisco

WELCOME

SPEAKERS

AGENDA

PARTNER WITH US

REGISTER YOUR PLACE

Showcase your brand and services in front of leading experts in the longevity industry

Partnering with the **4th Annual Longevity Therapeutics Summit** is your opportunity to highlight your expertise, elevate your company's standing, and display your influence to the community in front of all of those investing in novel technologies in longevity therapeutics.

Demonstrate how your services can help the industry **streamline and optimize their drug development pipeline** on the way to regulatory approval. Partnership opportunities include speaking on the agenda, hosting in-person networking sessions and exhibiting your products to our focused audience. We will work with you to build a bespoke partnership package to **maximize your exposure** and **align with your 2022 business objectives**. Get in touch today to learn discover how you can get involved and make meaningful connections within the longevity therapeutics community.



Secure an exhibition booth to **showcase your expertise and educate the industry on how you can support and streamline their efforts**



Network in-person **and build new relationships with senior level decision-makers from leading pharma and biotech companies**



Secure a branding or speaking opportunity to **demonstrate your thought leadership, drive your brand exposure and differentiate yourself from competitors**




Meet your 2022 commercial objectives and educate key decision makers on how your expertise can help ensure longevity therapeutics achieve their full potential and reach patients in need

Very professional event. Great timing

Co-Founder and CEO, **Elevian**




TYPES OF COMPANIES ATTENDING*



*Based on previous editions of the Longevity Therapeutics Summit

SENIORITY OF ATTENDEES*



GET INVOLVED



Kieran Crewe
Partnerships Director
Tel: (+1) 6174554188
Email: sponsor@hansonwade.com



Ready to Register?



June 28-30, 2022
San Francisco

3 Easy Ways To Book

- www.longevity-therapeutics.com/take-part/register
- Tel: +1 617 455 4188
- Email: register@hansonwade.com

- 1 Reunite with **in-person** with your colleagues in the longevity therapeutics community
- 2 Access key knowledge from diverse perspectives to **accelerate your pipeline towards the clinic** and develop truly curative anti-aging therapies
- 3 **Deep-dive** into **exclusive case studies** around cellular senescence, telomere attrition, loss of proteostasis, epigenetic reprogramming, stem cell exhaustion, mitochondria, and much more

Secure Your Place Now

Drug Developer Pricing	Book By June 28 & Save Up To \$100	On The Door
Full Access Pass: conference + 2 workshops	\$3,897 (Save \$100)	\$3,997
Conference + 1 workshop	\$3,390 (Save \$100)	\$3,498
Conference only	\$2,899 (Save \$100)	\$2,999
Academic & Not-for-Profit Pricing	Book By June 28 & Save Up To \$100	On The Door
Full Access Pass: conference + 2 workshops	\$3,297 (Save \$100)	\$3,397
Conference + 1 workshop	\$2,898 (Save \$100)	\$2,998
Conference only	\$2,499 (Save \$100)	\$2,599
Solution/ Service Provider Pricing	Book By June 28 & Save Up To \$100	On The Door
Full Access Pass: conference + 2 workshops	\$4,697 (Save \$100)	\$4,797
Conference + 1 workshop	\$4,098 (Save \$100)	\$4,198
Conference only	\$3,499 (Save \$100)	\$3,599

All prices shown in USD. To qualify for the drug developer rate your company must have a public drug pipeline. Please visit the website for full pricing options or email info@hansonwade.com

Are you an academic or work in a not-for-profit organization? Email us at info@hansonwade.com to inquire about our discounted rates

Team Discounts*

- **20% discount – 5 or more delegates**
- **15% discount – 4 delegates**
- **10% discount – 3 delegates**

Make the most of **4th Annual Longevity Therapeutics Summit** by attending with colleagues or registering your team. By attending as a group, you and your colleagues can get the most of the pre-conference workshops and networking sessions to ensure you leave with valuable connections and actionable insights

*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time and are automatically applied at checkout.



VENUE

Marines' Memorial Club & Hotel
609 Sutter St, San Francisco, CA 94102, United States
www.marinesmemorial.org

TERMS & CONDITIONS

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London EC1Y 0TH